NASDAQ · CELC
Healthcare · Biotechnology
$82.70
Up+$0.22 (+0.27%)
Updated Sep 16, 2026, 5:59 PM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CELC does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CELC.
CELC research
Company profile and research snapshot.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Citizens | Market Outperform | — |
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 14, 2026 | Needham | Buy | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Celcuity Inc. (CELC) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman...
Yahoo · Sep 1, 2026
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on T
Yahoo · Aug 27, 2026
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company’s history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone […]
SeekingAlpha · Aug 27, 2026
Kazia Therapeutics' pipeline is validated by recent PI3K/AKT/mTOR pathway approvals and acquisitions.. Read more on KZIA stock here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CELC.
